Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal sales" in 2024. Analysts' concerns were heightened by the company's revised sales forecast for 2024, which projects $3 billion to $3.1 billion, falling at the low end of previous estimates.
Moderna cuts 2025 sales forecast by $1 billion on weak vaccine demand, shares fall
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 18% in premarket trading.
Moderna Stock Plunges After Vaccine Sales Struggle
Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its vaccines against Covid-19 and respiratory syncytial virus continue to be sluggish.
Moderna shares plunge after company cuts vaccine sales outlook
The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.
Moderna cuts 2025 sales view on slow start to RSV shot, weak COVID vaccine demand
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow launch of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines. It expects $1.5 billion to $2.5 billion in annual revenue,
Moderna Shares Drop to Five-Year Low After Slashing Revenue, Sales Forecasts
Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance. Shares fell 22% to $33.
Moderna shares plunge as company dramatically lowers sales forecast
Axios Visuals Moderna shares plunged today to lows not seen since the early weeks of the pandemic after the company dramatically lowered its sales forecast. Zoom in: Waning demand for COVID vaccines is crushing Moderna's revenue.
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 24% in early trading.
Moderna Cuts 2025 Revenue Forecast by $1 Billion, Shares Drop 17% As Investors Eye $30 Support Level
Moderna shares tumbled nearly 17% on Monday after the drugmaker slashed its 2025 revenue forecast by $1 billion and announced plans to cut $1.5 billion in expenses this year. The company faces challenges balancing rising drug development costs with declining demand for Covid-19 treatments and slow adoption of its RSV medication.
Moderna May Have The Best Shot At A Vaccine For Stomach Flu
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
Moderna surprises the Street by predicting a bigger-than-expected sales drop
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year ...
Moderna’s Financial Outlook: Hold Rating Amidst Competitive Challenges and Strategic Adjustments
In a report released today, Terence Flynn from Morgan Stanley assigned a Hold rating on Moderna (MRNA – Research Report), with a price target ...
AI could solve greatest human challenges, if we let it, Moderna cofounder says
Combining human efforts, nature, and AI in what Noubar Afeyan calls “polyintelligence” could solve problems such as climate ...
Why Moderna Stock Just Crashed 21%
Moderna 's ( MRNA -20.49%) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...
Moderna Faces Financial Uncertainty Amid Market Competition and Revenue Challenges
Analyst Mani Foroohar of Leerink Partners maintained a Sell rating on Moderna (MRNA – Research Report), reducing the price target to ...
Moderna's Road To Stopping The Red
Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...
Is Moderna Stock a No-Brainer Buy on the Sell-Off?
Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...